The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules
Abstract
BACKGROUND: Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) is a potentially useful but expensive test to diagnose solitary pulmonary nodules. OBJECTIVE: To evaluate the cost-effectiveness of strategies for pulmonary nodule diagnosis and to specifically compare strategies that did and did not include FDG-PET. DESIGN: Decision model. DATA SOURCES: Accuracy and complications of diagnostic tests were estimated by using meta-analysis and literature review. Modeled survival was based on data from a large tumor registry. Cost estimates were derived from Medicare reimbursement and other sources. TARGET POPULATION: All adult patients with a new, noncalcified pulmonary nodule seen on chest radiograph. TIME HORIZON: Patient lifetime. PERSPECTIVE: Societal. INTERVENTION: 40 clinically plausible combinations of 5 diagnostic interventions, including computed tomography, FDG-PET, transthoracic needle biopsy, surgery, and watchful waiting. OUTCOME MEASURES: Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The cost-effectiveness of strategies depended critically on the pretest probability of malignancy. For patients with low pretest probability (26%), strategies that used FDG-PET selectively when computed tomography results were possibly malignant cost as little as 20 000 dollars per QALY gained. For patients with high pretest probability (79%), strategies that used FDG-PET selectively when computed tomography results were benign cost as little as 16 000 dollars per QALY gained. For patients with intermediate pretest probability (55%), FDG-PET strategies cost more than 220 000 dollars per QALY gained because they were more costly but only marginally more effective than computed tomography-based strategies. RESULTS OF SENSITIVITY ANALYSIS: The choice of strategy also depended on the risk for surgical complications, the probability of nondiagnostic needle biopsy, the sensitivity of computed tomography, and patient preferences for time spent in watchful waiting. In probabilistic sensitivity analysis, FDG-PET strategies were cost saving or cost less than 100 000 dollars per QALY gained in 76.7%, 24.4%, and 99.9% of computer simulations for patients with low, intermediate, and high pretest probability, respectively. CONCLUSIONS: FDG-PET should be used selectively when pretest probability and computed tomography findings are discordant or in patients with intermediate pretest probability who are at high risk for surgical complications. In most other circumstances, computed tomography-based strategies result in similar quality-adjusted life-years and lower costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Probabilistic Sensitivity Analysis Using Monte Carlo Simulation: A Practical Approach
Doubilet, P., Begg, C. B., Weinstein, M. C., Braun, P., & McNeil, B. J. (1985) · Medical Decision Making · doi:10.1177/0272989x8500500205 · Cited by 860 · cited 3×
“We assigned logit-normal distributions to all costs and probabilities for all diagnostic test variables by using the method of Doubilet and colleagues (77) and performed 10 000 simulations by randomly sampling values from these distributions.”
BackgroundMethodInfluential
Cited by
Evaluation of Individuals With Pulmonary Nodules: When Is It Lung Cancer?
Gould, M. K., Donington, J., Lynch, W. R., Mazzone, P. J., Midthun, D. E., Naidich, D. P., & Wiener, R. S. (2013) · Chest · doi:10.1378/chest.12-2351 · Cited by 1,450
Self-citationRecommendations on the Use of 18F-FDG PET in Oncology
Fletcher, J. W., Djulbegovic, B., Soares, H. P., Siegel, B. A., Lowe, V. J., Lyman, G. H., Coleman, R. E., Wahl, R., Paschold, J. C., Avril, N., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.047787 · Cited by 1,101
Computer analysis of computed tomography scans of the lung: a survey
Sluimer, I., Schilham, A., Prokop, M., & van Ginneken, B. (2006) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2005.862753 · Cited by 556
Evaluation of Patients With Pulmonary Nodules: When Is It Lung Cancer?
Gould, M. K., Fletcher, J., Iannettoni, M. D., Lynch, W. R., Midthun, D. E., Naidich, D. P., & Ost, D. E. (2007) · Chest · doi:10.1378/chest.07-1353 · Cited by 503
Self-citationState-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
Siebert, U., Alagoz, O., Bayoumi, A. M., Jahn, B., Owens, D. K., Cohen, D. J., & Kuntz, K. M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.014 · Cited by 588
Self-citation
Metadata
- Authors
- Gould, M. K., Sanders, G. D., Barnett, P. G., Rydzak, C. E., Maclean, C. C., McClellan, M. B., & Owens, D. K.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2003-05-06
- Volume
- 138
- Issue
- 9
- Pages
- 724-735
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1985409655
- Cited by
- 172
- References
- 1
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules. https://app.cochat.ai/papers/10.7326/0003-4819-138-9-200305060-00009
- The paper
- Gould, M. K., Sanders, G. D., Barnett, P. G., Rydzak, C. E., Maclean, C. C., McClellan, M. B., & Owens, D. K. (2003). Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-138-9-200305060-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.